We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Oct 2021
  • Code : CMI4698
  • Pages :189
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders. More than 40 genes have been identified in CMT, and each gene is associated with one or more diseases. In addition, several genes can be associated with one type of CMT. More than half of CMT cases are caused due to duplication of the PMP22 gene on chromosome 17. There are different types of CMT diseases, such as CMT1 (caused by myelin sheath abnormalities), CMT2 (peripheral nerve cell axon abnormalities), and CMT3 or dejerine-sottas disease is a particularly serious demyelinating neuropathy, that begins in infancy.

The global charcot-marie-tooth disease market is estimated to be valued at US$ 793.9 Million in 2021 and is expected to increase to US$ 3,459.1 Million by 2028, witnessing a CAGR of 23.4% over the forecast period (2021-2028).

Figure 1. Global Charcot-Marie-Tooth Disease Market Value (US$ Mn) & Y-o-Y Growth (%)

CHARCOT-MARIE-TOOTH DISEASE MARKET

To learn more about this report, request a free sample copy

Increasing prevalence of charcot-marie-tooth disease is expected to drive the growth of the global charcot-marie-tooth disease market.

Increasing prevalence of charcot-marie-tooth disease is expected to drive the growth of the global charcot-marie-tooth disease market. For instance, according to the information provided by MedlinePlus in September 2020, charcot-marie-tooth disease is the most common genetic disease, involving peripheral nerves and affecting the population. One in every 3,300 people in the world is affected by the disease. Furthermore, according to the same source, 70% to 80% of CMT1 patients have mutations that affect the PMP22 gene. Most of these situations occur when there are extra copies of the gene due to a small duplication of genetic material on chromosome 17. Another 10% to 12% of CMT1 patients have mutations in the MPZ gene. The most common cause of CMT2 is a mutation in the MFN2 gene, which accounts for about 20% of cases of total CMT cases. Approximately 90% of CMTX patients have mutations in the GJB1 gene.

Charcot-Marie-Tooth Disease Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 793.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 23.4% 2028 Value Projection: US$ 3,459.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: CMT 1, CMT 2, CMT 3, Others
  • By Drug Type: Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics, Pipeline Drug
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.

Growth Drivers:
  • Increasing incidence and prevalence of CMT
  • Development of Novel Therapeutics for the Treatment of CMT Disease
Restraints & Challenges:
  • Increased risk of tumor recurrence 
  • Difficulty of diagnosis due to high treatment costs

Figure 2. Global Charcot-Marie-Tooth Disease Market Share (%), By Region, 2021

CHARCOT-MARIE-TOOTH DISEASE MARKET

To learn more about this report, request a free sample copy

Global Charcot-Marie-Tooth Disease Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sector, which is majorly impacted by the COVID-19 pandemic.

The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments.

Global Charcot-Marie-Tooth Disease Market: Restraint

The increased risk of tumor recurrence and the difficulty of diagnosis due to high treatment costs have hindered the global charcot-marie-tooth disease market.

Key Players

Major players operating in the global charcot-marie-tooth disease market include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.

Frequently Asked Questions

The global charcot-marie-tooth market size is estimated to be valued at US$ 793.9 Million in 2021 and is expected to exhibit a CAGR of 23.4% between 2021 and 2028.

Increasing incidence and prevalence of CMT and development of novel therapeutics for the treatment of CMT disease are major driving factors for the market.

CMT 1 is the major disease type segment in the market.

The increased risk of tumor recurrence and the difficulty of diagnosis due to high treatment costs are the major factor restraining growth of the market.

Major players operating in the market include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo